Feladilimab

CAS No. 2252518-85-5

Feladilimab( —— )

Catalog No. M36892 CAS No. 2252518-85-5

Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 511 In Stock
10MG 787 In Stock
25MG 1169 In Stock
50MG 1535 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Feladilimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist.
  • Description
    Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX | PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2252518-85-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Offidani M, et al. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther. 2021 Jun 2;15:2401-2415.?
molnova catalog
related products
  • Dexketoprofen tromet...

    Dexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations.

  • Acacetin

    Acacetin has anti-plasmodial activity and anti-peroxidant activity.

  • Inulicin

    Inulicin, an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.